In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 801-809

  Peeters, Elke ^a   Nelis, Hans J ^a   Coenye, Tom ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Antibiotics; Bactericidal; Bacteriostatic; Biofilms; Cystic fibrosis

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; MEROPENEM; MINOCYCLINE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOPLANKTON; BACTERIOSTASIS; BIOFILM; BROTH DILUTION; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; BIOFILMS; BURKHOLDERIA CEPACIA COMPLEX; COLONY COUNT, MICROBIAL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 70349446193     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp253     Document Type: Article

References (37)

1. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 2005; 3: 144-56.
2. Vandamme P, Holmes B, Vancanneyt M et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997; 47: 1188-200.
3. Coenye T, Vandamme P, Govan JRW et al. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001; 39: 3427-36.
4. Vanlaere E, LiPuma JJ, Baldwin A et al. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol 2008; 58: 1580-90.
5. Vanlaere E, Baldwin A, Gevers D et al. Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int J Syst Evol Microbiol 2009; 59: 102-11.
6. Mahenthiralingham E, Baldwin A, Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol 2002; 51: 533-8.
7. Speert DP. Advances in Burkholderia cepacia complex. Paediatr Respir Rev 2002; 3: 230-5.
8. Nzula S, Vandamme P, Govan JRW. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother 2002; 50: 265-9.
9. Burns JL. Antibiotic resistance of Burkholderia spp. In: Coenye T, Vandamme P, eds. Burkholderia: Molecular Microbiology and Genomics Norfolk: Horizon Bioscience, 2007; 81-91.
10. Conway BAD, Venu V, Speert DP. Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex. J Bacteriol 2002; 184: 5678-85.
11. Tomlin KL, Clark SRD, Ceri H. Green and red fluorescent protein vectors for use in biofilm studies of the intrinsically resistant Burkholderia cepacia complex. J Microbiol Methods 2004; 57 95-106.
12. Aaron SD, Ferris W, Henry DA et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-12.
13. Zhou J, Chen Y, Tabibi S et al. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2007; 51: 1085-8.
14. Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: A randomised, double-blind, controlled clinical trial. Lancet 2005; 366: 463-71.
15. Cystic Fibrosis Trust. Antibiotic Treatment For Cystic Fibrosis, Report of the UK Cystic Fibrosis Trust Antibiotic Group. 2nd edn. Bromley, Kent, UK: Cystic Fibrosis Trust, 2002.
16. National Committee for Clinical and Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Fourteenth Informational Supplement M100-S14. NCCLS, Wayne, PA, USA, 2004.
17. Spoering AL, Lewis K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 2001; 183: 6746-51.
18. Desai M, Bühler T, Weller PH et al. Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth. J Antimicrob Chemother 1998; 42: 153-60.
19. Dunne WM. Bacterial adhesion: Seen any good biofilms lately? Clin Microbiol Rev 2002; 15: 155-66.
20. Moriarty TF, McElnay JC, Elborn JS et al. Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 2007; 42: 1008-17.
21. Hasselmann C. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect 2003; 9: Ix-xv.
22. Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 2008; 72: 157-65.
23. Heersink J. Basic biofilm analytical methods. In: Hamilton M, Heersink J, Buckingham-Meyer K et al., eds. The Biofilms Laboratory: Step-By-Step Protocols for Experimental Design, Analysis, and Data Interpretation. Bozeman: Cytergy Publishing, 2003; 16-23.
24. Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 2005; 26: 305-8.
25. Eisenberg J, Pepe M, Williams-Warren J et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997; 111: 955-62.
26. Geller DE, Rosenfeld M, Waltz DA et al. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003; 123: 28-36.
27. Weidmann A, Webb AK, Dodd ME et al. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. J Cyst Fibros 2008; 7: 409-11.
28. Caraher E, Reynolds G, Murphy P et al. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro. Eur J Clin Microbiol Infect Dis 2007; 26: 213-6.
29. Moskowitz SM, Foster JM, Emerson J et al. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42: 1915-22.
30. Ceri H, Olson ME, Stremick C et al. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities. J Clin Microbiol 1999; 37: 1771-6.
31. Hill D, Rose B, Pajkos A et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic and biofilm conditions. J Clin Microbiol 2005; 43: 5085-90.
32. Walters MC, Roe F, Bugnicourt A et al. Contributions of antibiotic penetration, oxygen limitation and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2002; 47: 317-23.
33. Anwar H, Costerton JW. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990; 34: 1666-71.
34. Sauer K, Camper AK, Ehrlich GD et al. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 184: 1140-54.
35. Brown MRW, Collier PJ, Gilbert P. Influence of growth rate on susceptibility to antimicrobial agents: Modification of the cell envelope and batch and continuous culture studies. Antimicrob Agents Chemother 1990; 34: 1623-8.
36. Anwar H, Strap JL, Chen K et al. Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin. Antimicrob Agents Chemother 1992; 36: 1208-14.
37. Keays T, Ferris W, Vandemheen KL et al. A retrospective analysis of biofilm antibiotic susceptibility testing: A better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009; 8: 122-7.